Chemomab Therapeutics Ltd DRC
$ 1.64
-2.96%
30 Dec - close price
- Market Cap 10,094,400 USD
- Current Price $ 1.64
- High / Low $ 1.83 / 1.60
- Stock P/E N/A
- Book Value 1.82
- EPS -1.44
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.41 %
- ROE -0.73 %
- 52 Week High 9.84
- 52 Week Low 1.60
About
Chemomab Therapeutics Ltd. is a clinical-stage biopharmaceutical company based in Tel Aviv, Israel, focused on developing groundbreaking biological therapies for inflammatory and fibrotic diseases. Its lead product candidate, CM-101, is a monoclonal antibody designed to inhibit key pathways implicated in fibrosis, showcasing potential across various therapeutic areas. With a commitment to advancing innovative solutions, Chemomab leverages its proprietary technology platform to address significant medical challenges, striving to enhance patient outcomes and quality of life in underserved populations. The company’s strategic focus on meeting critical healthcare needs positions it as a promising player in the biopharmaceutical landscape.
Analyst Target Price
$17.50
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-07 | 2025-08-14 | 2025-05-07 | 2025-03-05 | 2024-11-14 | 2024-08-21 | 2024-05-09 | 2024-03-07 | 2023-11-09 | 2023-08-14 | 2023-05-11 | 2023-03-20 |
| Reported EPS | -0.004 | -0.016 | -0.007 | -0.008 | -0.01 | -0.26 | -0.2753 | -0.2654 | -0.02 | -0.036 | -0.8 | -0.04 |
| Estimated EPS | -0.005 | -0.1 | -0.01 | -0.01 | -0.01 | -0.01 | -0.03 | -0.02 | -0.02 | -0.03 | -0.04 | -0.04 |
| Surprise | 0.001 | 0.084 | 0.003 | 0.002 | 0 | -0.25 | -0.2453 | -0.2454 | 0 | -0.006 | -0.76 | 0 |
| Surprise Percentage | 20% | 84% | 30% | 20% | 0% | -2500% | -817.6667% | -1227% | 0% | -20% | -1900% | 0% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CMMB
2025-12-04 23:09:30
Chemomab Therapeutics announced the publication of positive Phase 2 SPRING trial results for nebokitug in primary sclerosing cholangitis (PSC) in the American Journal of Gastroenterology. The data indicate nebokitug was generally safe, well-tolerated, and showed dose-dependent improvements in key biomarkers, particularly in patients with moderate/advanced fibrosis. These findings support advancing nebokitug to a Phase 3 registration trial.
2025-12-03 21:08:59
Chemomab Therapeutics Ltd. announced positive results from its Phase 2 SPRING trial for nebokitug in primary sclerosing cholangitis (PSC), published in the American Journal of Gastroenterology. The drug demonstrated safety and improvements in inflammation and fibrosis biomarkers, particularly at the 20 mg/kg dose in patients with moderate to advanced fibrosis. These findings support advancing nebokitug to a Phase 3 registration trial, with the company's shares seeing an 8.26% gain over the past week.
2025-12-03 05:20:53
Chemomab Therapeutics announced the publication of its Phase 2 SPRING trial results for nebokitug in primary sclerosing cholangitis (PSC) in the American Journal of Gastroenterology. The study indicated that nebokitug was safe and well-tolerated, showing numerical improvements in inflammation and fibrosis biomarkers, particularly at the 20 mg/kg dose and in patients with moderate/advanced fibrosis. These promising results support the advancement of nebokitug to a Phase 3 registration trial for PSC, a severe liver disease with no cure.
2025-12-03 05:20:53
Chemomab Therapeutics announced positive results from its Phase 2 SPRING trial for nebokitug in primary sclerosing cholangitis (PSC), indicating the drug is safe and well-tolerated. The trial showed disease-modifying potential with numerical improvements in biomarkers for inflammation and fibrosis, particularly at higher doses and in patients with advanced fibrosis. These findings support advancing nebokitug to a Phase 3 registration trial for this rare liver disease.
2025-12-02 08:00:00
Chemomab Therapeutics announced the publication of nebokitug's Phase 2 SPRING trial results in the American Journal of Gastroenterology. The study indicates nebokitug is generally safe and well-tolerated, showing numerical improvements in inflammation and fibrosis biomarkers for Primary Sclerosing Cholangitis (PSC) patients, particularly those with moderate/advanced fibrosis. These promising findings support further evaluation in a Phase 3 clinical trial for PSC, a chronic liver disease with high unmet medical need.
2025-11-25 23:09:27
Chemomab Therapeutics Ltd. (Nasdaq: CMMB) announced that co-founder and CEO Adi Mor, PhD, will participate in Oppenheimer's Movers in Rare Disease Summit on December 11, 2025, in New York City. The invitation-only summit will feature panels, presentations, and one-on-one investor meetings with companies focused on rare diseases. Dr. Mor will present a corporate overview and be available for individual meetings with registered attendees.
